The Elecsys® Anti-SARS-CoV-2-S test can detect the level of antibodies to the spike protein of the SARS-CoV-2 coronavirus. Since the spike protein is the target of many COVID-19 vaccines, this test may be used to characterize vaccine-induced immune response.
"We are proud of what we have accomplished so far to support the efforts of
How does the Elecsys® Anti-SARS-CoV-2-S work?
The new Elecsys® Anti-SARS-CoV-2-S test measures the level of antibodies against SARS-CoV-2 in patients who have been exposed to the virus or vaccinated, which is important in establishing potential immunity and vaccine efficacy. This immunoassay targets antibodies against the viral spike protein, specifically its receptor-binding-domain (RBD), which is the common target for virus neutralizing antibodies and the focus of therapeutics and vaccine design.
"The presence and level of such antibodies could signal whether a person has already been infected and potentially developed immunity to the virus, said
The Elecsys® Anti-SARS-CoV-2-S test is the latest addition to the comprehensive
In
About Elecsys Anti-SARS-CoV-2-S and Elecsys Anti-SARS-CoV-2 serology tests
The Elecsys® Anti-SARS-CoV-2-S is an immunoassay for the in vitro qualitative and semi-quantitative detection of antibodies to SARS-CoV-2 spike protein receptor binding domain in human serum and plasma. Through a blood sample, the test is intended as an aid to assess the adaptive humoral immune response to the SARS–CoV–2-S protein. The test may also detect a response to vaccination2.
The test has both a high clinical specificity of 99.97% (N=13 871) and sensitivity of 98.8% (N=1423), 14 days or later after diagnosis with PCR. Additionally, across panels of potentially cross-reactive samples (N=1468) from endemic human coronaviruses, infectious respiratory diseases, other infectious diseases, auto-immune and liver related diseases, the test demonstrated zero cross-reactivity.
Hospitals and reference laboratories can run the test on
About
As a leading healthcare company, we are committed to minimize the impact of COVID-19, and help save and improve lives.
- Launching COVID-19 diagnostic tests for active infection and the detection of antibodies in patients who have been exposed to the virus
- Investigating treatments from our existing portfolio to better understand their potential to treat patients with COVID-19
- Increasing manufacturing and supply chain capacity to meet product demand across our portfolio within the wider context of COVID-19 treatment
- Ensuring the supply of our existing medicines and diagnostics to patients under exceptional conditions.
About
All trademarks used or mentioned in this release are protected by law. |
____________________________________ |
1 Zhu FC et al. (2020). Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial. |
2 The performance of the device has not been assessed on specimens from individuals who have been infected with emerging variants of SARS-CoV-2 of public health concern. |
3 Full specifications of the |
SOURCE
© Canada Newswire, source